If you watch television, you've probably come across a commercial for AndroGel, AbbVie's (ABBV 0.77%) blockbuster prescription gel for treating low testosterone levels. The technical term for the ailment is hypogonadism, and it's a $2 billion market -- and growing. Markets like that don't come without admirers, and in this case one of those is Repros Therapeutics (NASDAQ: RPRX). The company is developing an oral drug for secondary hypogonadism called Androxal, and in the following video Brenton Flynn discusses why its stock soared today.
